We searched PubMed for articles published from January, 1964, until May, 2011, in English, with the terms “neurotransmitter”, “monoamine”, “dopamine”, “serotonin”, “HVA”, “HIAA”, “5-HIAA”, “dopa responsive dystonia”, “autosomal dominant GTP cyclohydrolase 1 deficiency”, “autosomal recessive GTP cyclohydrolase 1 deficiency”, “sepiapterin reductase deficiency”, “dihydropteridine reductase deficiency”, “6-pyruvoyltetrahydropterin synthase deficiency”, “tyrosine hydroxylase deficiency”, “aromatic
ReviewThe monoamine neurotransmitter disorders: an expanding range of neurological syndromes
Introduction
Brain neurotransmission is an essential process for neuronal differentiation and growth, as well as for the development of interneuronal communication and neuronal circuitry.1 Inherited abnormalities in neurotransmitter synthesis, breakdown, and transport represent an expanding group of neurometabolic syndromes with important therapeutic implications.2 Symptoms are determined by the type and severity of the disorder and are dominated by neurological features, including developmental delay, pyramidal and extrapyramidal motor disorders, epilepsy, autonomic dysfunction, and neuropsychiatric symptoms. Overall, the clinical phenotype mimics that of many other neurological disorders and, therefore, misdiagnosis or diagnostic delay are common. Onset can occur at any age but is most frequently in infancy or early childhood.
Neurotransmitter disorders are due to aberrant metabolism or transport of the biogenic amines, glycine, vitamin B6, GABA, and glutamic acid.2, 3, 4 The biogenic amines are a functionally important group of brain neurotransmitters5 and consist of the catecholamines (dopamine, norepinephrine, and epinephrine) and serotonin. Dopamine and serotonin have key roles in the brain, including the control of locomotion, mood, and behaviour.
In this Review, we focus on the monoamine neurotransmitter disorders that lead to depletion in availability of dopamine, serotonin, or both. We aim to clearly define the clinical, biochemical, and molecular genetic features of disorders of pterin, dopamine, and serotonin metabolism (figure 1, table). A practical guide to specialist diagnostic investigations and a comprehensive therapeutic approach to each monoamine neurotransmitter disorder will also be discussed.
Section snippets
Role of dopamine and serotonin
Metabolism of dopamine and serotonin in the brain are postulated to be closely linked at biochemical and physiological levels (figure 2).8, 9 Dopamine was thought to be a purely intermediary substrate in the biosynthesis of norepinephrine and epinephrine, until the 1950s, when Carlsson and colleagues10 discovered that dopamine was present in high concentrations in the rat corpus striatum. Administration of reserpine, which blocked the vesicular monoamine transporter, led to dopamine depletion
Neurological investigations
The diagnosis of a monoamine neurotransmitter disorder is established on the basis of clinical history, physical examination, biochemical investigations, enzyme analysis (for some disorders), and analysis of genetic mutations (figure 3).28 The specific pattern of neurotransmitter metabolites can be indicative of a particular neurotransmitter disorder (figure 3).
Autosomal dominant GTPCH deficiency
Autosomal dominant GTPCH deficiency (Online Mendelian Inheritance in Man mutation number [OMIM] #128230; also known as Segawa disease, DYT 5a, and dopa-responsive dystonia) was first clinically reported in the 1970s. Segawa and colleagues40, 41 described a syndrome of extrapyramidal basal ganglia features with a striking response to levodopa and, in one adult with a 43-year clinical course, hereditary progressive dystonia with notable diurnal fluctuation.41
Age of disease onset is generally
Disorders of selective serotonin deficiency
A distinct group of patients present with motor disorders associated with an isolated deacrease in 5-HIAA production. Naumann and colleagues84 have reported a series of adult patients with idiopathic adult-onset dystonia in which 5-HIAA levels were significantly lower than those in controls. 5-HIAA concentrations might also be reduced in other adult neurological disorders, such as cerebellar tremor, neuropsychiatric disorders, and Alzheimer's disease. The observation that patients with dystonia
Secondary neurotransmitter disorders
Neurotransmitters abnormalities indicative of dopamine or serotonin depletion are becoming increasingly recognised as secondary phenomena in several neurological disorders. Concentrations of HVA and 5-HIAA in CSF in such patients are mostly within the range deemed abnormal for primary neurotransmitter disorders, but generally do not reach the lowest levels.
A secondary reduction in HVA is reported in perinatal asphyxia, disorders of folate metabolism, phenylketonuria, Lesch-Nyhan disease,
Conclusions
The monoamine neurotransmitter disorders are an expanding group of neurological syndromes, many of which present in infancy and early childhood (table). They are important to recognise because they are frequently misdiagnosed and many show a good clinical response to treatment. Increased clinical awareness, reliable and reproducible biochemical testing, and advances in molecular genetic testing have improved delineation of the phenotypic spectrum of such disorders. Analysis of neurotransmitters
Search strategy and selection criteria
References (90)
- et al.
Neurotransmitters and neuromodulators during early human development
Early Hum Dev
(2001) - et al.
Inherited disorders of neurotransmitters in children and adults
Clin Biochem
(2005) - et al.
Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy
Am J Hum Genet
(2005) The loading of neurotransmitters into synaptic vesicles
Biochimie
(2000)- et al.
Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF
J Psychiatr Res
(1986) - et al.
Monoamine distribution in primate brain-IV. Indoleamine-containing perikarya in the brain stem of Macaca arctoides
Neuroscience
(1982) - et al.
Monoamine distribution in primate brain. V. Monoaminergic nuclei: anatomy, pathways, and local organization
Brain Res Bull
(1982) Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals
Neuroscience
(1981)- et al.
Altered behavioral responses mediated by serotonin receptors in the genetically dystonic (dt) rat
Brain Res Bull
(1991) - et al.
Serotonin: a regulator of neuronal morphology and circuitry
Trends Neurosci
(2010)